What Is Good vs. Bad Cholesterol? HDL, LDL Explained

HDL and LDL are both lipoproteins, tiny protein-wrapped packages that carry cholesterol through your blood. LDL earned the “bad cholesterol” label because it delivers cholesterol into artery walls, where it can build up and eventually trigger heart disease. HDL picked up the “good cholesterol” tag because it does roughly the opposite, ferrying cholesterol away from arteries and back to the liver for disposal. That framing has held up reasonably well over decades of research, but the real picture is more layered than two neat categories suggest.

What LDL Actually Does in Your Arteries

LDL particles carry the bulk of cholesterol circulating in your blood, and the trouble starts when they cross the inner lining of your artery walls. For a long time, researchers assumed LDL seeped through passively, the way water leaks through a cracked pipe. More recent work has shown that the process is active: the cells lining your arteries pull LDL across using specific receptor proteins and transport machinery, regardless of whether the lining is damaged.¹

Once LDL particles get trapped in the artery wall, they undergo chemical changes. Oxidation is the primary one: the particle’s fatty cargo reacts with oxygen-related molecules, creating a modified form that triggers inflammation.² Immune cells rush in to gobble up the oxidized LDL, swell into foam cells, and gradually form fatty streaks that grow into plaques. Over years, those plaques narrow arteries and can rupture, causing heart attacks or strokes. This chain of events, from LDL entry to plaque formation, is what makes LDL the central villain in cardiovascular disease.

Not All LDL Particles Are the Same

Your standard blood test reports LDL cholesterol as a single number, but LDL particles come in different sizes. Some are large and buoyant; others are small and dense. Research over the past few decades has consistently shown that small, dense LDL particles carry more risk than their larger counterparts. In one early prospective study, men with the smallest LDL particles had roughly a 3.6-fold higher risk of heart disease compared to men with the largest, and that association held even after accounting for other lipid measurements.³

Several properties make small, dense LDL worse. These particles have a harder time binding to the liver’s LDL receptors, so they linger in the bloodstream longer. They are more easily oxidized. And they stick more readily to the structural molecules inside artery walls.⁴ Data from the large ARIC study found that increasing levels of small, dense LDL cholesterol tracked with rising heart disease risk in a stepwise fashion, while levels of large LDL particles showed no such pattern.⁵

So two people with identical LDL cholesterol numbers can have very different risk profiles depending on the size distribution of their particles. Most routine blood panels do not break this down, though advanced testing (like nuclear magnetic resonance-based lipid panels) can.

How HDL Earns Its Good Reputation

HDL particles act as cholesterol scavengers. They pick up excess cholesterol from cells throughout your body, including cells in artery walls, and carry it back to the liver. The liver then recycles the cholesterol or converts it into bile acids for excretion. This whole circuit is called reverse cholesterol transport, and it is HDL’s signature protective function.⁶

Like LDL, HDL particles are not all identical. They come in different sizes and carry different protein passengers, which affect how well they do their job. Larger HDL particles, for instance, tend to be associated with better cardiovascular outcomes.⁷ Exercise appears to shift the balance toward these larger, more functional HDL particles, on top of raising total HDL levels.⁸

Why Raising HDL Has Not Panned Out as Expected

If HDL is protective, you might assume that drugs designed to push HDL levels higher would prevent heart disease. That intuition drove billions of dollars in pharmaceutical development, and the results were a major disappointment. Several drugs called CETP inhibitors successfully raised HDL cholesterol by large amounts but failed to reduce heart attacks and strokes. One drug in that class, anacetrapib, did show a modest cardiovascular benefit, but researchers concluded the benefit came primarily from the drug’s LDL-lowering effect, not from the HDL increase.⁹

The lesson from these trials reshaped how researchers think about HDL. A high HDL number on a blood test is still statistically linked to lower cardiovascular risk, but artificially inflating that number with drugs does not produce the expected payoff. What seems to matter more is how well your HDL particles actually function, specifically how efficiently they pull cholesterol out of artery walls and deliver it to the liver. That functional quality is harder to measure than a simple blood level, and it is not captured on a routine lipid panel.

Beyond HDL and LDL

The “good vs. bad” framework leaves out some players that are increasingly recognized as important.

Lipoprotein(a)

Lipoprotein(a), usually written Lp(a), is an LDL-like particle with an extra protein called apolipoprotein(a) attached. It promotes plaque formation through a combination of mechanisms: it is atherogenic like regular LDL, but it also has inflammatory and clot-promoting properties.¹⁰ Your Lp(a) level is largely determined by your genes, with roughly 70 to 90 percent of the variation between people being inherited.¹⁰ That means diet and exercise barely budge it. Levels in the general population can range from less than 1 mg/dL to over 1,000 mg/dL.¹¹

Most people have never had their Lp(a) measured, because it is not included in a standard lipid panel. Given that it is a genetically fixed and independent risk factor, many cardiology experts now recommend measuring it at least once in a person’s lifetime so that those with very high levels can manage their other risk factors more aggressively.¹²

Remnant Lipoproteins

When your body digests fat, it packages it into large triglyceride-rich particles. As these particles shed their triglyceride load, they shrink into smaller leftovers called remnants. These remnant particles carry a lot of cholesterol and can infiltrate artery walls much like LDL does. Multiple lines of evidence, including genetic studies, now point to remnant cholesterol as a contributor to cardiovascular disease that operates independently of LDL cholesterol.¹³¹⁴ People with high triglycerides tend to have more remnant particles, which is one reason elevated triglycerides predict heart trouble even when LDL looks acceptable.

ApoB as a Better Scoreboard

Every LDL particle, every remnant particle, and every Lp(a) particle contains one copy of a protein called apolipoprotein B (apoB). HDL does not carry apoB. That makes apoB a convenient single number that captures the total count of all the “bad” particles circulating in your blood, regardless of size or type. A growing body of evidence suggests that apoB may be a better predictor of cardiovascular risk than standard LDL cholesterol alone.

A recent analysis from the UK Biobank found that when apoB and LDL particle number disagreed, it was apoB that tracked with risk. Even a small discordance of about 2 percent in apoB was associated with a statistically higher rate of major cardiovascular events and coronary artery disease. At 30 percent discordance, the risk for coronary disease was roughly 2.5 times higher.¹⁵ Some guidelines have already started incorporating apoB as a secondary or even primary lipid target, particularly in people whose standard LDL cholesterol might underestimate their true risk, such as those with high triglycerides or diabetes.

What You Eat and What Ends Up in Your Blood

One of the most persistent misconceptions about cholesterol is that eating cholesterol-rich foods directly raises your blood cholesterol by a proportional amount. The reality is more nuanced. Your body produces most of its own cholesterol in the liver, and when you eat more cholesterol, your liver compensates by dialing production down. This feedback loop is well documented, though the degree of compensation varies a lot from person to person.¹⁶ Some people compensate almost completely, while others barely adjust at all.¹⁷ This individual variability is why the old blanket advice to avoid eggs has softened considerably. Dietary cholesterol matters for some people, but it is not the main dietary driver of blood cholesterol for most.

The types of fat you eat have a larger and more consistent effect. Saturated fats raise LDL cholesterol, though different saturated fats vary in potency.¹⁸ Trans fats are the worst offender by far: they raise LDL and simultaneously lower HDL. In a controlled feeding study, swapping oleic acid (the main fat in olive oil) for trans fats raised LDL cholesterol while dropping HDL cholesterol, a double hit that no other common dietary fat replicates.¹⁹ Industrial trans fats have been largely phased out of food supplies in many countries, which is one of the clearer public-health wins of the past two decades.

How Exercise Reshapes Your Lipid Profile

Regular aerobic exercise tends to raise HDL, lower LDL, and reduce triglycerides.²⁰ But the benefits go beyond shifting a few numbers on a lab report. Exercise also improves the functional quality of HDL, enhancing how effectively those particles participate in reverse cholesterol transport.²¹ And as noted earlier, exercise shifts the distribution of both LDL and HDL particles toward larger, less harmful subtypes: more large LDL (less dangerous), fewer small dense LDL, and more large HDL.⁸

The magnitude of these changes from exercise alone is usually modest, enough to meaningfully lower risk but rarely enough to normalize lipid levels in someone with a genetic predisposition to high cholesterol. That is where medications come in.

Medications That Lower LDL

Statins remain the first-line treatment. They work by blocking an enzyme in the liver that is essential for cholesterol production, which forces liver cells to pull more LDL out of the bloodstream to meet their needs.²² For people who need more LDL lowering than a statin can deliver, or who cannot tolerate statins, there are several add-on options. Ezetimibe blocks cholesterol absorption in the gut, and PCSK9 inhibitors (injected antibodies) prevent the liver from breaking down its own LDL receptors, keeping more receptors available to clear LDL from the blood.²³

A newer approach, inclisiran, uses a technology called RNA interference to silence the gene that produces PCSK9 in the liver. The practical advantage is dosing: after initial loading doses, inclisiran requires only two injections per year and reduces LDL cholesterol by roughly half.²⁴ This is particularly relevant for people who struggle with adherence to daily pills, which is a major reason why real-world cholesterol control lags behind what clinical trials suggest is possible.

When Genetics Override Everything Else

Familial hypercholesterolemia (FH) is a genetic condition that dramatically raises LDL cholesterol from birth. The most common cause is mutations in the gene encoding the LDL receptor, the protein on liver cells responsible for pulling LDL out of the blood. Mutations in other genes, including those for apolipoprotein B and PCSK9, can produce the same effect.²⁵ People with FH can have LDL levels two to four times the normal range, and those with the most severe receptor mutations tend to develop more advanced artery disease earlier.²⁵

FH is estimated to affect roughly one in 250 people in its heterozygous form, making it one of the most common inherited metabolic disorders. Many people with FH are undiagnosed because they look healthy and may not get their cholesterol checked until middle age, by which point significant artery damage may already have accumulated. A very high LDL level in a young person, especially with a family history of early heart disease, should raise suspicion for FH and prompt further evaluation.

Your Gut Bacteria Play a Role Too

The relationship between gut bacteria and cholesterol is an area of active research that is still taking shape. Your intestinal microbes produce metabolites that influence cholesterol metabolism in several ways. They convert primary bile acids into secondary bile acids, which alters how much cholesterol the liver recycles. They produce trimethylamine from dietary compounds, which the liver converts to TMAO, a molecule linked to higher cardiovascular risk. And they generate short-chain fatty acids during fiber fermentation, which appear to have broadly beneficial metabolic effects.²⁶

One particularly interesting finding is that certain gut microbes can convert cholesterol directly into coprostanol, a form that the body does not absorb and simply excretes. Researchers have identified a specific microbial enzyme responsible for this conversion.²⁷ The practical implications are still speculative, but the idea that your microbiome’s composition could partially determine how much dietary cholesterol you absorb adds another layer of explanation for why individuals respond so differently to the same diet.

How Cholesterol Testing Has Evolved

The standard lipid panel, which reports total cholesterol, LDL, HDL, and triglycerides, has been the clinical workhorse since the mid-20th century. The LDL number most people see on their lab results is actually calculated from the other values using a formula, not measured directly. This works reasonably well most of the time but can be inaccurate when triglycerides are high. Advanced techniques like nuclear magnetic resonance (NMR) spectroscopy can directly measure particle numbers and sizes, including remnant cholesterol, but what NMR measures does not always match what the standard formula calculates.²⁸

For most people, the standard lipid panel provides enough information for clinical decisions. Advanced testing becomes more valuable in edge cases: someone with borderline LDL but a strong family history of heart disease, someone with high triglycerides and diabetes (where standard LDL calculations are less reliable), or someone already on treatment whose risk seems higher than their numbers suggest. Whether to request apoB measurement, Lp(a) testing, or NMR-based particle analysis is a conversation worth having with a clinician if you fall into one of those categories.